Foghorn Therapeutics Inc. (FHTX) Stock Grade

About Foghorn Therapeutics Inc.'s fundamentals

Foghorn Therapeutics is a biotechnology company with a market capitalization of $206.7 million that reported strong revenue growth of 36.8% year-over-year, indicating expanding business activity. However, the company is currently unprofitable, with a net margin of -240.3% and a reported net loss in its latest annual statement, which is typical for early-stage biotech firms investing heavily in research and development. The company does not pay a dividend. The elevated return on equity figure should be interpreted cautiously given the company's loss position.